IP Library Granted Patent US 10,898,497
Granted Patent B2
US 10,898,497 · App. 14/868,706 · Granted Jan 26, 2021

Compositions and methods for cartilage repair

Inventor: Christopher J. Centeno (Broomfield, CO)
Assignee: REGENEXX, LLC
A61K31/573A61K31/19A61K31/375A61K31/56A61K31/7088A61K35/16A61K35/19A61K35/28A61K38/1825A61K38/1841A61K38/1875A61K38/2006A61K38/363A61K45/06A61L2300/222
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,898,497
App. No.
14/868,706
Granted
Jan 26, 2021
Kind
B2
Abstract

Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.

Claims (14)

1. A method for facilitating cartilage repair in a patient in need thereof comprising:

preparing autologous platelet rich plasma;

obtaining autologous mesenchymal stem cells (MSCs) from bone marrow, peripheral blood, or adipose tissue of the patient; and

administering the MSCs, the autologous platelet rich plasma and one or more chondrogenesis inducing agents to a site in the patient in need of cartilage repair;

wherein the administration of the MSCs, the autologous platelet rich plasma and the one or more chondrogenesis inducing agents facilitates cartilage repair at the site in the patient in need of repair, and wherein at least one of the chondrogenesis inducing agents is a corticosteroid.

2. The method of claim 1 , further comprising administering platelet rich fibrin, whole cell platelet concentrate, a 5% to 40% platelet lysate solution obtained via freeze-thawing the platelets, or a mixture thereof to the patient in need thereof, and wherein the administration is at the site in the patient in need of repair.

3. The method of claim 1 wherein the administering step further comprises administering a carrier material comprising a gel, hydrogel, or foam.

4. The method of claim 1 , wherein the corticosteroid is dexamethasone.

5. The method of claim 1 , wherein the MSCs, the autologous platelet rich plasma, and the corticosteroid are combined prior to administration to the patient.

6. The method of claim 1 , wherein the autologous platelet rich plasma and the corticosteroid are combined prior to administration to the patient.

7. The method of claim 6 , wherein the autologous platelet rich plasma and corticosteroid is administered subsequently to the administration of the MSCs.

8. The method of claim 1 , wherein the autologous MSCs are obtained from bone marrow of the patient.

9. The method of claim 1 , wherein the autologous MSCs are obtained from peripheral blood of the patient.

10. The method of claim 1 , wherein the autologous MSCs are obtained from adipose tissue of the patient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2018
From: REGENERATIVE SCIENCES, LLC.
To: REGENEXX, LLC.
Reel/Frame 045961/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: CENTENO, CHRISTOPHER J.
To: REGENERATIVE SCIENCES, LLC
Reel/Frame 037456/0919 →
Continuity (4)
Continuation 13931572 · Jun 28, 2013
Continuation 12922436
Provisional Application 61036551 · Mar 14, 2008
Related Publication 20160015721A1 · Jan 21, 2016
Cited By (1)
US 12,304,974